Navigation Links
ACP recommends Stage 3 Meaningful Use focus on measuring improvements in health outcomes
Date:1/15/2013

PHILADELPHIA, January 15, 2013 -- Stage 3 Meaningful Use measures need to focus more on measuring improvements in patient health outcomes rather being than a large and growing collection of functional measures, the American College of Physicians (ACP) says in a letter submitted to the Health Information Technology Policy Committee (HITPC).

While praising the HITPC and its Meaningful Use Work Group for their diligence and hard work in developing recommendations for the Meaningful Use portion of the EHR Incentive Program, ACP noted that the proposed Stage 3 measures appear nearly identical in structure to those in previous stages.

"Stage 3 of Meaningful Use should encourage patients and practices to innovate, discovering creative ways to use the certified EHR technology they worked so hard to implement in Stages 1 and 2 and determining what has the greatest beneficial impact on the healthcare quality and value for patients, families and communities," said Michael H. Zaroukian, MD, PhD, FACP, FHIMSS, chair of ACP's Medical Informatics Committee and author of ACP's letter.

"A number of the proposed Stage 3 measures necessitate significant increases in clinical documentation, involve new and potentially complex workflows, are likely to be difficult for many eligible professionals to understand and implement, or depend on technologies that are not yet widely deployed or shown to be usable in busy practices," he added.

ACP's letter included the following specific concerns and suggestions:

  • Do not introduce new functions without appropriate testing.

  • Choose additional EHR provider note documentation requirements wisely and reduce existing requirements that do not add value.

  • Require usability testing with a specific focus on reducing data collection burdens.

  • Do not add functional requirements that have not been adequately defined.

  • Understand the implications of intensively focusing vendor programming capacity on Meaningful Use requirements, leaving them with little capacity to optimize the expanded capabilities added to meet Stage 1 and 2 certification criteria.

  • Consider the direct and indirect cost implications to EPs when adding new Meaningful Use requirements.

"We believe the some of the proposed Stage 3 requirements are likely to result in new, inefficient workflows and activities that shift physician focus away from the intended goal of patient-centered care and toward an excessive focus data collection for purposes that conflict with the physician's sense of what is most important for quality, safety, and value," Dr. Zaroukian said.

ACP noted its support of the comments offered by HIMSS Electronic Health Record Association (EHRA). In particular, ACP supports the following EHRA recommendations:

  • Focus primarily on encouraging and assisting providers to take advantage of the substantial capabilities established in Stages 1 and especially Stage 2, rather than adding many new meaningful use requirements and product certification criteria.

  • Given recent experience with Stage 2, reconsider and extend the timeline for initiating Stage 3.

  • Meaningful use and functionality changes for Stage 3 should focus on interoperability as a priority area.

  • Invest in quality measure alignment, infrastructure, and standards.

ACP also asked the HITPC to consider previous comments about Stage 2 for its final recommendations regarding Stage 3 Meaningful Use measures.


'/>"/>
Contact: Steve Majewski
smajewski@acponline.org
215-351-2514
American College of Physicians
Source:Eurekalert

Related medicine news :

1. American Cancer Society recommends informed decision making in lung cancer screening
2. FDA Panel Recommends Against 1st Drug for Chronic Fatigue Syndrome
3. VCU medical team recommends preventive antibiotic for COPD sufferers
4. APA task force recommends treatment guidelines and position statements on transgender persons
5. Task force recommends new lung cancer screening guidelines
6. Study Recommends Putting Your Left Face Forward
7. Study recommends ways to evaluate end-of-life care in nursing homes
8. Comparable patterns of failure between SBRT, lobectomy or pneumonectomy for stage I NSCLC
9. Fox Chase researchers discover novel role of the NEDD9 gene in early stages of breast cancer
10. Nobel laureate James Watson publishes novel hypothesis on curing late-stage cancers
11. MCG faculty member, former hostage returns to Kuwait as Fulbright Scholar
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... PITTSBURGH, PA (PRWEB) , ... December 09, 2016 , ... ... treatments," said an inventor from Winchester, Va. "I thought that if the nebulizer had ... their treatments rather than fearing them." , He developed the patent-pending NEBY to avoid ...
(Date:12/8/2016)... ... December 08, 2016 , ... After enjoying ... opened registration today for its 33rd Annual Issues & Research Conference, March ... The theme of the conference is “Persistent Challenges and New Opportunities: Using Research ...
(Date:12/8/2016)... ... December 08, 2016 , ... ... Medication Therapy Management (MTM), adherence, and other pharmacist-delivered patient care services, has announced ... counsel and Eric Hoessel to vice president of sales. , Litsinger joined ...
(Date:12/8/2016)... ... December 08, 2016 , ... Premier Fitness Camp (PFC) and The Chopra Center ... loss and wellness program, at their world headquarters of Omni La Costa Resort & ... results to anyone seeking weight loss, personal development, a healthy lifestyle, or mental and ...
(Date:12/8/2016)... (PRWEB) , ... December 08, 2016 , ... ... Medical Center has been recognized for adherence to the highest standards of ... medical accreditation organizations, announced the center's president and CEO, Dr. Daniel Messina. , ...
Breaking Medicine News(10 mins):
(Date:12/8/2016)... 8, 2016  Eli Lilly and Company (NYSE: ... phase 3 EXPEDITION3 trial at the 9 th ... disclosed, solanezumab did not meet the primary endpoint in ... in people with mild dementia due to Alzheimer,s disease ... solanezumab for the treatment of mild dementia due to ...
(Date:12/8/2016)... -- Research and Markets has announced the addition of ... Type, Application, Usability - Forecast to 2025" report to their ... , , ... to grow at a CAGR of around 3.2% from 2015 to ... include advancements in extracellular microelectrode arrays and intracellular microelectrodes, research in ...
(Date:12/8/2016)...   TriNetX , the health research network, ... signed a membership agreement to join the network ... cures. The TriNetX network is comprised ... globally, biopharmaceutical companies and contract research organizations (CROs) ... site selection, patient recruitment, and collaborative research across ...
Breaking Medicine Technology: